In this article an infectious diseases pharmacist discusses five interesting things to know about sulopenem (Orlynvah). Authored by: Tina Zheng, Pharm.D., BCIDP Article Posted 15 January 2025 Sulopenem etzadroxil and probenecid (Orlynvah) was recently approved in October 2024 for the treatment of uncomplicated urinary tract infections (uUTI) caused by … [Read more...]
2024 IDstewardship Year End Review
In this article we do a quick run down on IDstewardship for the end of 2024. Article Posted January 2025 It was welcomed that 2024 did not feel like an extension of the 2020 COVID-19 pandemic as 2021-2023 had. I think many of us working in the infectious diseases space were grateful not to be at the mercy of pandemic demands. 2024 was a slower year for … [Read more...]
Five Lessons Learned About Antimicrobial Stewardship Metrics
In this article an experienced antimicrobial stewardship pharmacist discusses lessons learned from navigating antimicrobial stewardship metrics. Authored by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Article posted December 2024 If you cannot measure it, you cannot determine if you have changed it. Antimicrobial stewardship metrics are essential … [Read more...]
Year In Review: Top Infectious Diseases Articles From 2024
In this article a selection of notable peer-reviewed publications from 2024 are provided. Article Selection by: Bassam Ghanem, Pharm.D., MS, BCPS, BCIDP Article Construction by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP 2024 has been an interesting year for infectious disease literature dissemination. For years many of us were using #IDtwitter to get … [Read more...]
5 Ways To Celebrate Antibiotic Awareness Week 2024
This article discusses ways to celebrate the annual observance of antibiotic awareness week 2024. Written by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP Each year for one week the United States Centers for Disease Control and Prevention (CDC) observes U.S. Antibiotic Awareness Week (USAAW) and encourages others to participate in the event. The USAAW … [Read more...]